Douglas L. Looker - Lafayette CO Izydor Z. Apostol - Boulder CO Eric A. Brucker - Evergreen CO Michael P. Doyle - Boulder CO David L. Foster - Lafayette CO Christopher B. Glascock - Louisville CO James C. Hartman - Boulder CO Geoffrey F. Lee - Boulder CO Douglas D. Lemon - Louisville CO Edwin G. Moore - Boulder CO Jane P. Richards - Longmont CO Michael R. Schick - Louisville CO Stephen P. Trimble - Boulder CO David Pereira - Apex NC Ton-That Hai - Mundelein IL Kenneth E. Burhop - Longmont CO
Assignee:
Baxter International, Inc. - Deerfield IL Baxter Healthcare S.A. - Kanton Zurich
International Classification:
C07K 14805
US Classification:
514 6, 535385
Abstract:
The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
Douglas L. Looker - Fort Lupton CO, US Izydor Z. Apostol - Boulder CO, US Eric A. Brucker - Evergreen CO, US Michael P. Doyle - Boulder CO, US David L. Foster - Lafayette CO, US Christopher B. Glascock - Louisville CO, US James C. Hartman - Boulder CO, US Geoffrey F. Lee - Boulder CO, US Douglas D. Lemon - Louisville CO, US Edwin G. Moore - Boulder CO, US Jane P. Richards - Longmont CO, US Michael R. Schick - Louisville CO, US Stephen P. Trimble - Boulder CO, US David Pereira - Apex NC, US Ton-That Hai - Mundelein IL, US Kenneth E. Burhop - Longmont CO, US
Assignee:
Baxter International, Inc. - Deerfield IL Baxter Healthcare S.A. - Zurich
International Classification:
A61K 35/14
US Classification:
514 6, 530385
Abstract:
The invention relates to novel hemoglobin compositions, particularly novel recombinant mutant hemoglobin compositions, which eliminate or substantially reduce 1) the creation of heart lesions, 2) gastrointestinal discomfort, 3) pressor effects, and 4) endotoxin hypersensitivity associated with the administration of extracellular hemoglobin compositions in various therapeutic applications. Applications described include treatments for anemia, head injury, hemorrhage or hypovolemia, ischemia, cachexia, sickle cell crisis and stroke; enhancing cancer treatments; stimulating hematopoiesis; improving repair of physically damaged tissues; alleviating cardiogenic shock; and shock resuscitation.
Mar 2011 to 2000 GMD Training Operations Contract SupportNGC Colorado Springs, CO May 2006 to Nov 2009 Deputy Experimentation Lab (X-Lab) LeadNGC for Honeywell Colorado Springs, CO Sep 2004 to Jun 2005 Requirements and Interfaces Section Lead for the Satellite Communications Network Contract (SCNC)TRW for Smithsonian Astrophysical Observaotry Cambridge, MA Aug 1997 to Aug 2004 Senior System EngineerRaytheon at Hanscom AFB Bedford, MA Sep 1994 to Mar 1996 System Engineer on Air Warfare Simulator Re-Engineering (AWSIM/R)TRW for Raytheon Wayland, MA Sep 1990 to Jan 1993 Test Director for Cobra Dane System ModernizationTRW Colorado Springs, CO 1987 to 1989 Subproject Manager for Human Factors EngineeringTRW Redondo Beach, CA 1981 to 1986 Operational Flight Software Subproject Manager for the B-2 Stealth Bomber Program
Education:
University of Illinois Champaign, IL 1975 B.S. in Math/Computer Science